Evolving Strategies in the Management of HER2-Positive Early-Stage Breast Cancer - a podcast by ReachMD

CME credits: 0.25

Valid until: 29-03-2022

Claim your CME credit at https://reachmd.com/programs/cme/evolving-strategies-management-her2-positive-early-stage-breast-cancer/12412/

Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.

In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD